Is there a role for lung surgery in initially unresectable non-small cell lung cancer after tyrosine kinase inhibitor treatment?

Nguk Chai Diong1, Chia-Chuan Liu2*, Chih-Shiun Shih2, Mau-Ching Wu3, Chun-Jen Huang4 and Chen-Fang Hung5

Abstract
Background: The role of lung surgery in initially unresectable non-small cell lung cancer (NSCLC) after tyrosine kinase inhibitor (TKI) treatment remains unclear. We aimed to assess the survival benefits of patients who underwent surgery for regressed or regrown tumors after receiving TKI treatment.

Methods: The details of patients diagnosed with unresectable NSCLC treated with TKI followed by lung resection from 2010 to 2020 were retrieved from our database. The primary endpoint was 3-year overall survival (OS), whereas the secondary endpoints were a 2-year progression-free survival (PFS), feasibility, and the safety of pulmonary resection. The statistical tests used were Fisher’s exact test, Kruskal Wallis test, Kaplan-Meier method, Cox proportional hazards model, and Firth correction.

Results: Nineteen out of thirty-two patients were selected for the study. The patients underwent lung surgery after confirmed tumor regression (17 [89.5%]) and regrowth (two [10.5%]). All surgeries were performed via video-assisted thoracoscopic surgery: 14 (73.7%) lobectomies and five (26.3%) sublobar resections after a median duration of 5 months of TKI. Two (10.5%) postoperative complications and no 30-day postoperative mortality were observed. The median postoperative follow-up was 22 months.

The 2-year PFS and 3-year OS rates were 43.9% and 61.5%, respectively. Patients who underwent surgery for regressed disease showed a significantly better OS than for regrowth disease (HR = 0.086, 95% CI 0.008–0.957, \( p = 0.046 \)). TKI-adjuvant demonstrated a better PFS than non-TKI adjuvant (HR = 0.146, 95% CI 0.027–0.782, \( p = 0.025 \)).

Conclusion: Lung surgery after TKI treatment is feasible and safe and prolongs survival via local control and directed consequential therapy. Lung surgery should be adopted in multimodality therapy for initially unresectable NSCLC.

Keywords: Epidermal growth factor receptor (EGFR), Molecular targeted therapy, Non-small cell lung cancer (NSCLC), VATS

Background
Lung cancer is the top-ranked cancer-related cause of death worldwide [1]. Approximately 85% of lung cancers are non-small cell lung cancers (NSCLCs). More than 70% of these cases are diagnosed at stages III and IV [2], which are mainly unresectable. The definition of "unresectable" in lung cancer is subjective, and consensus on its definition is currently lacking [3]. Generally,
unresectable NSCLC is represented by stage III NSCLC, in which the tumor is >7 cm in diameter or invades adjacent structures (T4), multistations, or bulky mediastinal lymph nodes (N2-3), and stage IV disease, in which distant metastasis (M1) is detected. Conventionally, the treatment for unresectable stage III NSCLC is concurrent platinum-based doublet chemotherapy and radiotherapy (CCRT), whereas for stage IV NSCLC is chemotherapy. These treatments yield low 5-year overall survival (OS) rates of 15% and 0–10% for stage III and stage IV disease, respectively [4, 5].

In the last two decades, significant advancements in molecular-targeted therapy have caused a paradigm shift in the standard treatment of metastatic NSCLC. Tyrosine kinase inhibitors (TKI), molecular-targeted drugs, inhibit specific oncogenic drivers, such as the epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK), which trigger cancer evolution. Multiple randomized trials have demonstrated the superiority of TKI treatment in stage IV NSCLC, with a better objective response rate (ORR, 60–80%), progression-free survival (PFS, 9–13 months), and toxicity safety profile than standard chemotherapy [6–11]. Hence, the American Society of Clinical Oncology, European Society for Medical Oncology, and National Comprehensive Cancer Network adopted EGFR-TKI and ALK-TKI as first-line therapies for EGFR- and ALK-positive advanced NSCLC, respectively [12–14].

The main drawback of TKI therapy is disease progression within approximately 1 year of administration because of acquired resistance [6–11], limiting its long-term use. During TKI therapy, the tumor may respond by shrinking to residual disease or remain stable to regrow. Consensus on the role of surgical resection for these lesions is lacking.

The role of TKI as neoadjuvant therapy remains unclear. Because of its low toxicity profile and rapid and outstanding ORR, TKI may help downstage unresectable stage III NSCLC to a resectable state in a favorable duration while maintaining the patient’s performance status.

We aimed to evaluate the effect of lung surgery on residual or regrowth lesions after TKI therapy in initially unresectable NSCLC patients by assessing the survival rate and the feasibility and safety of the surgery.

**Methods**

**Study design and patients**

We retrieved the records of all patients diagnosed with NSCLC who underwent lung resection after TKI therapy from our hospital database between January 2010 and December 2020. The inclusion criteria were patients diagnosed with unresectable NSCLC, TKI treatment followed by lung surgery, and no previous lung surgery before TKI therapy. We accepted patients who received chemotherapy, radiotherapy, or both before TKI therapy.

Clinical staging was established according to the eighth edition of the American Joint Committee on Cancer TNM with chest computed tomography (CT) for pulmonary lesions, brain magnetic resonance imaging to exclude brain metastasis and positron emission tomography–CT for nodal involvement and presence of distant metastasis.

An unresectable tumor was defined as a tumor exceeding a 7-cm diameter or direct tumor invasion into adjacent structures (T4), where resection may be deemed incomplete or in the N2-3 state for stage III NSCLC and distant metastasis for stage IV NSCLC. TKI was administered as neoadjuvant therapy for unresectable stage III NSCLC, for which radical resection was expected after the therapy. Patients with stage IV NSCLC were treated with TKI for which lung resection was considered only when the disease was converted to localized disease.

All treatment decisions were made based on tumor board discussion. Patients received TKI monotherapy based on the status of the molecular alterations: EGFR mutation with EGFR-TKI and ALK translocation with ALK-TKI. These patients were followed up with chest CT every 1 to 3 months to evaluate the response to TKI in the pulmonary and metastatic lesions according to the response evaluation criteria for solid tumors (RECIST 1.1).

Tumor regression was defined as a reduction of >30% in the size of the primary tumor after TKI treatment compared to the CT imaging size at diagnosis. Tumor regrowth was defined as an increase of >20% in the size of the primary tumor despite ongoing TKI treatment.

The feasibility and safety of pulmonary surgery were assessed based on surgery type and approach, the number of lymph nodes dissected, completeness of surgical resection, surgery duration, intraoperative blood loss, postoperative complications, and 30-day postoperative mortality. Patients with peripheral tumor and size <2 cm in diameter were subjected to sublobar resection. Otherwise, standard lobectomy and systemic lymphadenectomy were performed.

Postoperatively, adjuvant therapy was provided based on the resected pathology results. Surveillance was conducted every 3 months with chest CT for the first 3 years, followed by surveillance every 6 months.

The Institutional Review Board approved the study (IRB number 20220117A, dated 24 January 2022) and waived the requirement for informed consent from the patients.
Endpoints
The primary endpoint was the 3-year OS after lung surgery. The secondary endpoints were 2-year PFS and feasibility and the safety of pulmonary surgery after TKI treatment.

Statistical analysis
PFS was calculated from the surgery date to the date of disease relapse, whereas OS was calculated from the date of surgery to the date of patient death or last evaluation. Differences in demographics and clinical characteristics were performed using Fisher’s exact test for categorical data and Kruskal-Wallis test for continuous data. The Saphiro-Wilk test was used to test the normality of the data. The Cox proportional hazards model and Firth correction method were used to calculate the hazard ratio (HR) and corresponding 95% confidence intervals (CIs). A $p<0.05$ was considered statistically significant. Survival curves were estimated using the Kaplan–Meier method and compared with log-rank test curves. Statistical analyses were performed using the SAS software (v.9.4; SAS Institute, Inc., Cary, NC).

Results
Patient and clinical characteristics
Among the 32 patients enrolled, five previously had lung surgery, four exhibited a poor response to TKI and switched to other therapies before the lung surgery, two received TKI after lung surgery, and two received inconsistent TKI treatment. Nineteen out of the thirty-two patients were selected for analysis (Fig. 1).

The demographic data and clinical characteristics of all enrolled patients are listed in Table 1. All but one patient with stage III squamous cell carcinoma (SCC) were confirmed to have adenocarcinoma and tested for EGFR mutation and ALK rearrangement at diagnosis. This one patient was subjected to EGFR-TKI (erlotinib) after failed definitive chemotherapy and radiotherapy and responded with stable disease for 5 years, at which point the tumor started to regrow. The patient underwent salvage pulmonary resection, and the pathology revealed adenosquamous carcinoma and wild-type for EGFR and ALK.

The median duration of preoperative TKI administration was 5 months (0.8–66.0 months). Indications for surgery included regressed disease in 17 (89.5%) cases and tumor regrowth in two (10.5%) cases.

Safety of surgery
All patients underwent video-assisted thoracoscopic surgery (VATS), with lobectomy performed in 14 (73.7%) patients and sublobar resection in five (26.3%) patients (Table 2). Seventeen out of nineteen patients (89.5%) had complete tumor resection (R0), and two (10.5%) had R2 resection. Two patients (10.5%) developed postoperative complications: bleeding and thoracic empyema. Both complications were managed by VATS evacuation of clots and decortication. No postoperative mortality was reported within 30 days.

![Flow chart for case selection](image-url)

**Fig. 1** Flow chart for case selection. NSCLC, non-small cell lung cancer; TKI, tyrosine kinase inhibitor; PFS, progression-free survival; OS, overall survival.
Outcomes after surgery

Postoperatively, 13 (68.4%) patients continued with the same TKI therapy, except one who switched to osimertinib because of a positive T790M mutation from the specimen (Table 2). The remaining patients received adjuvant chemotherapy, radiotherapy, or both. Nine (47.4%) patients developed relapse at a median duration of 13 months (6–41 months): intrathoracic recurrence or metastases, two (10.5%); distant metastases, three (15.8%); and both, four (21.1%). The median duration of postoperative follow-up was 22 months (1–85 months).
The 2-year PFS and 3-year OS rates were 43.9% and 61.5%, respectively (Table 3 and Fig. 2), with median PFS and OS values of 17 and 50 months, respectively.

Prognostic factors of PFS and OS after lung surgery
Univariate analysis identified patients who underwent surgery for regressed disease was associated with significant better OS than regrowth disease (HR=0.086, 95% CI 0.008–0.957, \(p=0.046\)) and adjuvant TKI treatment showed better PFS than non-TKI adjuvant treatment (HR=0.146, 95% CI 0.027–0.782, \(p=0.025\)). Preoperative stage I/II after TKI treatment showed poorer PFS than stage III disease (HR 4.377, CI 95% 1.083–17.691, \(p=0.038\)) (Table 3).

Discussion
The observed 3-year OS of 61.5% with a median OS of 50 months from lung surgery after TKI therapy for initially unresectable stage III and IV NSCLC is encouraging. This value generally exceeded the 3-year OS and a median OS of stages III and IV, 7–55%, and 6–29 months, respectively [5, 15]. In addition to the efficacy of TKI therapy, the contribution of lung resection should be highlighted to achieve this milestone.

The development of molecular-targeted therapy has allowed patients to gain extraordinary responses to treatment with less toxicity. Therefore, advanced NSCLC patients are expected to live longer with improved treatment options and maintained Eastern Cooperative Oncology Group (ECOG) status, particularly in oligometastatic NSCLC, as observed in our cohort. Oligometastasis is defined as five or fewer metastases that involve three or fewer organs [16] and has a better prognosis than the general stage IV cohort, with a 5-year OS of 30 vs. 0–10% [5, 17, 18]. Hence, oligometastatic NSCLC deserves aggressive treatment, including primary lung resection.

Gomez et al. demonstrated comprehensive local consolidation therapy (LCT) after systemic therapy in which local therapy applied to primary and metastatic lesions of NSCLC significantly prolonged PFS and OS than maintenance therapy and observation: PFS was 14.2 vs. 4.4 months and OS was 41.2 vs. 17.7 months for LCT vs. maintenance therapy, respectively [19]. Mitchell et al. compared the LCT for primary lung lesions

### Table 3 Factors associated with overall survival and progression-free survival

| Variable                                      | Overall survival |                      | Progression-free survival |                      |
|-----------------------------------------------|------------------|-----------------------|---------------------------|-----------------------|
|                                               | HR   | 95% CI   | \(p\) | HR   | 95% CI   | \(p\) |
| Gender                                        | 0.927 | 0.154–5.563 | 0.934 | 0.424 | 0.103–1.739 | 0.234 |
| ECOG 0 vs 1                                   | 5.497 | 0.542–66.801 | 0.150 | 0.873 | 0.217–3.511 | 0.849 |
| Histopathology: Adenocarcinoma vs SCC         | 0.087 | 0.005–1.393 | 0.084 | 0.299 | 0.024–1.652 | 0.166 |
| Genetic mutation: EGFR vs ALK                 | 0.580 | 0.015–39.800 | 0.277 | 2.003 | 0.243–260.278 | 0.657 |
| Clinical stage: III vs IV                     | 0.853 | 0.152–4.794 | 0.857 | 1.632 | 0.437–6.095 | 0.466 |
| Preoperative stage: I/II vs III               | 3.205 | 0.582–17.663 | 0.181 | 4.377 | 1.083–17.691 | 0.038 |
| ypStage: I/II/III vs IV                      | 0.207 | 0.018–2.320 | 0.202 | 0.221 | 0.062–1.900 | 0.344 |
| Indication for TKI: Neoadjuvant vs treatment  | 0.375 | 0.043–3.287 | 0.376 | 1.184 | 0.294–4.764 | 0.812 |
| Indication for surgery: Regressed vs regrowth | 0.086 | 0.008–0.957 | 0.046 | 0.299 | 0.054–1.652 | 0.166 |
| Surgery: Lobectomy vs sublobectomy            | 0.348 | 0.031–3.853 | 0.289 | 0.904 | 0.179–4.566 | 0.903 |
| Completeness resection: R0 vs R2              | 4.828 | 0.431–54.077 | 0.202 | 2.911 | 0.526–16.100 | 0.221 |
| Postoperative TKI adjuvant: Yes vs no         | 0.506 | 0.099–2.587 | 0.413 | 0.146 | 0.027–0.782 | 0.025 |
| Relapse: Yes vs no                            | 6.268 | 0.701–825.479 | 0.259 |            |              |     |

ECOG Eastern Cooperative Oncology Group, EGFR epidermal growth factor receptor, ALK anaplastic lymphoma kinase, SCC squamous cell carcinoma, TKI tyrosine kinase inhibitor, HR hazard ratio, CI confidence interval
treated with surgery to radiotherapy for oligometastatic NSCLC and observed superior 5-year OS in the surgery group (48.0 vs. 24.2%) [20]. Compared to radiation and ablation therapy, surgery has the following advantages: obtaining a valuable specimen for the complete assessment of tumor response to treatment, exploring the resistance mechanism, evaluating actionable biomarkers to direct subsequent treatment, overcoming acquired resistance, reducing the amount of circulating tumor cells and tumor heterogeneity, and enhancing the subsequent systemic therapy effect [21, 22].

Evidence for the benefit of lung surgery after TKI therapy is scarce, as shown by the limited number of patients reported in most published papers (Table 4) [23–26]. The median PFS and OS values ranged from 10 to 15 and 17 to 68 months, respectively. Compared to previous studies, our median PFS was higher (17 months), whereas our median OS was within the previously reported range. Pulmonary resection after TKI therapy is technically challenging because of the dense scar tissue formed at the pleura and hilum as a sequela of the tissue reaction to the treatment. Consequently, extended operating

Table 4 Comparing our results with other studies

| Study                  | n   | Duration of TKI, m | Clinical stage, n (%) | Surgery, n (%)                  | Post operative complications, n | Adjuvant TKI, Y/N/U | PFS/OS, m |
|------------------------|-----|--------------------|-----------------------|---------------------------------|---------------------------------|---------------------|-----------|
| Ohtaki et al. [23]     | 36  | 14                 | IIIA, 8 (22.2)        | Lobectomy, 28 (77.8)            | Bleeding, 1                     | 16/20/0             | 15/58     |
|                        |     |                    | III B, 4 (11.1)       | Segmentectomy, 3 (8.3)          | Empyema, 1                      |                     |           |
|                        |     |                    | IV, 21 (58.3)         | Wedge resection, 2 (5.6)        |                                 |                     |           |
|                        |     |                    | R, 3 (8.3)            | Bilobectomy, 1 (2.8)            |                                 |                     |           |
|                        |     |                    |                       | Pneumonectomy, 2 (5.6)         |                                 |                     |           |
| Song et al. [24]       | 9   | 6 (2–46)           | IIIA, 2 (22.2)        | Lobectomy, 9 (100%)             | Atrial fibrillation, 1          | 9/0/0               | 14/17     |
|                        |     |                    | IIIB, 1 (11.1)        |                                 |                                 |                     |           |
|                        |     |                    | IV, 6 (66.7)          |                                 |                                 |                     |           |
| Yamamoto et al. [25]   | 24  | 3 (0.7–36)         | II B, 1 (4.2)         | Lobectomy, 15 (62.5)            | Empyema, 1                      | 12/9/3              | 10/68     |
|                        |     |                    | IIIA, 8 (33.3)        | Bilobectomy, 5 (20.8)           | Chylothorax, 1                   |                     |           |
|                        |     |                    | IIIB, 5 (20.8)        | Pneumonectomy, 4 (16.7)         |                                 |                     |           |
|                        |     |                    | IV, 10 (41.7)         |                                 |                                 |                     |           |
| Ning et al. [26]       | 10  | 3 (3–5)            | IIIA, 2 (20)          | Lobectomy, 9 (90)               | Death, 1                        | 9/0/0               | 14/36     |
|                        |     |                    | IIIB, 8 (80)          | Pneumonectomy, 1 (10)           |                                 |                     |           |

CR complete response, TKI tyrosine kinase inhibitor, PFS progression-free survival, OS overall survival, R recurrent, U unknown, m month, Y yes, N No
hours and postoperative morbidity are anticipated. The complication and mortality rates observed in our study are compatible with those reported for VATS lobectomy (10.5 vs. 10–20% and 0 vs. 0–2%, respectively) [27, 28]. The favorable perioperative outcome was attributed to the good ECOG status, low toxicity profile of TKI, case selection, improvements in perioperative care, prevention of pneumonectomy, and minimally invasive surgery. Overall, lung surgery after TKI is feasible and safe with appropriate patient selection.

The National Health Insurance of Taiwan approved the prescription of osimertinib, a third-generation EGFR-TKI, as the treatment for acquired resistance to the EGFR T790M mutation at the end of the study period in 2020. Before then, the T790M test was not widely performed. As only one patient in the cohort tested T790M-positive, we could not evaluate the benefit of surgery for acquired resistance compared to the osimertinib treatment alone.

Several studies have shown that regressed disease is a better predictor for favorable OS and PFS than stable disease [29, 30]. Although our study revealed that patients with regressed disease had a better OS than regrowth disease, the disparity between regressed and regrowth diseases (89.5% and 10.5%, respectively) in a small study cohort made the comparison tenuous. Hence, a study with large cohorts is required to validate the findings.

Five patients with unresectable stage III NSCLC at diagnosis received TKI as neoadjuvant therapy for a median duration of 2.5 months, followed by radical resection. All achieved R0 resection. The 3-year OS showed superior results compared to the PACIFIC trial, in which a similar group of patients received durvalumab after standard CCRT therapy (61.5 vs. 56.7%) [31]. Wu et al. reported median and maximum time to response values of 1.7 and 3.9 months, respectively [29]. Takeda et al. reported a median time to response of 1 month with most patients achieving complete response and a partial response within 2 months [30]. We deduced that TKI is safe and effective for 1–4 months of administration as a neoadjuvant before undergoing radical resection.

Evidence of TKI as adjuvant therapy is rare. Riel et al. advocated the continuation of TKI after failed TKI treatment because some tumor cells remaining sensitive to EGFR inhibition [32]. These issues should all be resolved after complete resection, and logically, TKI should be discontinued. However, our study showed that TKI continuation after the lung surgery significantly prolonged PFS compared to non-TKI adjuvant therapy. TKI is believed to act as cytostatic instead of cytotoxic drug, and it cannot eliminate micrometastatic cancer cells. The ADAURA trial studied osimertinib as adjuvant therapy for resectable stages IB–IIIA EGFR-mutant NSCLC and showed a significantly longer 2-year disease-free survival than with placebo (90 vs 44%) [34]. These results clarified the role of TKI as adjuvant therapy, and further research is justified.

The limitations of this study include the following: it was a retrospective, single-arm investigation conducted at a single center with a small sample size, short follow-up, highly selected patients, and heterogeneity of patient characteristics and clinical course. All stage IV patients were clinically downstaged to M0 before surgery. All regrowth tumors exhibited solitary progression. Only patients with a favorable response to TKI treatment were recruited, and those with an inadequate response were excluded. These factors all lead to a better prognosis. A prospective study with a larger sample size and a nonsurgical control group for comparison is required to validate the role of lung surgery in this context.

Lung surgery for initially unresectable NSCLC after TKI therapy is feasible and safe, helps to solve the problem of acquired resistance, and prolongs survival by local control and directed consequential treatment via surgical specimen analysis. Surgery should be considered a part of multimodality treatment, particularly for patients with an excellent response to TKI treatment.

Abbreviations
NSCLC: Non-small cell lung cancer; TKI: Tyrosine kinase inhibitor; EGFR: Epidermal growth factor receptor; ALK: Anaplastic lymphoma kinase; OS: Overall survival; PFS: Progression-free survival; ORR: Objective response rate; VATS: Video-assisted thoracoscopic surgery.

Acknowledgements
Not applicable.

Authors’ contributions
NC Diong contributed to the collecting of the data, drafting the work, interpretation of the data, writing the manuscript, preparing the tables, and revising the manuscript. CC Liu contributed to the collecting of the data, drafting the work, interpretation of the data, preparing the tables, and revising the manuscript. CS Shih contributed to the collecting of the data, drafting the work, interpretation of the data, and preparing the tables. MC Wu contributed to the collecting of data, analyzing the data, performing the statistical tests, and prepared Fig. 2. All authors have agreed both to be personally accountable for the author’s own contributions and to ensure that questions related to the accuracy or integrity of any part of the work, even ones in which the author was not personally involved, are appropriately investigated, resolved, and the resolution documented in the literature. The authors read and approved the final manuscript.

Funding
The authors declare that they do not receive any funding.

Availability of data and materials
All data generated or analyzed during this study are included in this published article.
Declarations

Ethics approval and consent to participate
The Institutional Review Board of Koo Foundation Sun Yat-Sen Cancer Center approved the study (reference number: IRB number 20220117A, dated 24 January 2022). All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the Helsinki Declaration. This is a retrospective study and does not require collection of data prospectively, thus no further access to patients. The Institutional Review Board has waived the consent from the patients.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Division of Thoracic Surgery, Department of Surgery, Kuala Lumpur General Hospital, Kuala Lumpur, Malaysia. 2 Division of Thoracic Surgery, Department of Surgery, Koo Foundation Sun Yat-Sen Cancer Center, 125, Lide Road, Beito District, Taipei 11259, Taiwan. 3 Department of Medical Oncology, Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan. 4 Department of Pulmonary Medicine and Intensive Care Medicine, Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan. 5 Department of Research, Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan.

Received: 5 June 2022 Accepted: 4 November 2022
Published online: 26 November 2022

References

1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71:7–33.
2. Lemijabbar-Alaoui H, Hassan OU, Yang WY, Buchanan P. Lung cancer. Biology and treatment options. Biochim Biophys Acta. 2015;1856:189–210.
3. Suzuki S, Goto T. Role of Surgical Intervention in Unresectable Non-Small Cell Lung Cancer. J Clin Med. 2020;9:3881.
4. Aupérin A, Le Péchoux C, Rolland E, Curran WJ, Furuse K, Fournel P, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol. 2010;28:2181–90.
5. Goldstraw P, Chansky K, Crowley J, Ramji-Porta R, Asamura H, Eberhardt WE, et al. The IASLC Lung Cancer Staging Project: proposals for revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for lung cancer. J Thorac Oncol. 2016;11:39–51.
6. Inoue A, Kikiyashii K, Maemondo M, Sugawara S, Otsuzi S, Isebe H, et al. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel in clinically selected patients with advanced non-small-cell lung cancer with sensitive EGFR gene mutations (NEJ002). Ann Oncol. 2013;24:54–9.
7. Fukuoka M, WuYL, Thongprasert S, Sunpavanawong P, Leong SS, Siurampong V, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin-paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol. 2011;29:2866–74.
8. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsunotani J, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harboring mutations of the epidermal growth factor receptor (WTOG3405S): an open label, randomised phase 3 trial. Lancet Oncol. 2010;11:1121–8.
9. Zhou C, WuYL, Chen G, Feng J, Liu QG, Wang C, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12:735–42.
10. WuYL, Zhou C, HuCP, Feng J, Lu S, Huang Y, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15:213–22.
11. Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Melkhal T, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371:2167–77.
12. Masters GA, Temin S, Azzoli CG, Giaccone G, Baker SJ, Brahmer JR, et al. Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2015;33:3488–515.
13. Planchar D, Popat S, Kerr K, Novello S, Smit EF, Faire-Finn C, et al. Meta-static non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:n192–237.
14. Ettinger DS, Wood DE, Aisner DL, Akerley W, Baumer JD, Bharat A, et al. NCCN guidelines insights: non-small cell lung cancer, Version 2.2021. J Natl Compr Cancer Netw. 2021;19:254–66.
15. Ozkaya S, Fındık S, Dircan A, Ateç AG. Long-term survival rates of patients with stage IIB and IV non-small cell lung cancer treated with cisplatin plus vinorelbine or gemcitabine. Exp Ther Med. 2012;4:1035–8.
16. Dingemans AC, Hendriks LE, Berghmans T, Levy A, Hasan B, Fauire-Finn C, et al. Definition of synchronous oligometastatic non-small cell lung cancer-a consensus report. J Thorac Oncol. 2019;14:1109–19.
17. Loi M, Mazzella A, Mansuet-Lupo A, Bobbio A, Canny E, Magdeleinat P, et al. Synchronous Oligometastatic Lung Cancer Deserves a Dedicated Management. Ann Thorac Surg. 2019;107:1053–9.
18. Gao XL, Zhang KW, Tang MB, Zhang KJ, Fang LN, Liu W. Pooled analysis for surgical treatment for isolated adrenal metastasis and non-small cell lung cancer. Interact Cardiovasc Thorac Surg. 2017;24:1–7.
19. Gomez DR, Tang C, Zhang J, Blumschein GR Jr, Hernandez M, Lee JJ, et al. Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study. J Clin Oncol. 2019;37:1558–65.
20. Mitchell KG, Faraooqi A, Ludmir EB, Corsini EM, Sepesi B, Gomez DR, et al. Pulmonary resection is associated with long-term survival and should remain a therapeutic option in oligometastatic lung cancer. JThorac Cardiovasc Surg. 2021;161:1467–74.
21. Mitsudomi T, Suda K, Yatabe Y. Surgery for NSCLC in the era of personalized medicine. Nat Rev Clin Oncol. 2013;10:235–44.
22. Lin JJ, Shaw AT. Resisting resistance: targeted therapies in lung cancer. Trends Cancer. 2016;2:350–64.
23. Ohtaki Y, Shimizu K, Suzuki K, Suzuki K, Tsuboi M, Mitsudomi T, et al. Salvage surgery for non-small cell lung cancer after tyrosine kinase inhibitor treatment. Lung Cancer. 2021;153:108–16.
24. Song W, Di S, Liu J, Fan B, Zhao J, Zhou S, et al. Salvage surgery for advanced non-small cell lung cancer after targeted therapy: A case series. Thorac Cancer. 2020;11:1061–7.
25. Yamamoto Y, Kodama K, Maniwa T, Takeda M. Surgical resection of advanced non-small cell lung cancer after a response to EGFR TKI: presentation of two cases and a literature review. J Cardiothorac Surg. 2017;12:98.
26. Ning Y, Bao M, Yan X, Xie D, Jiang G. Surgery for advanced non-small cell lung cancer patient after epidermal growth factor receptor tyrosine kinase inhibitor neoadjuvant therapy. Ann Transl Med. 2018;6:407.
27. Whiston BA, Groth SS, Duval SJ, Swanson SJ, Maddaus MA. Surgery for early-stage non-small cell lung cancer: a systematic review of the video-assisted thoracoscopic surgery versus thoracotomy approaches to lobectomy. Ann Thorac Surg. 2008;86:2008–16.
28. Kiesewetter A, Lamatsch M, Zeier M. Video-assisted thoracoscopic sympathectomy of the superior cervical ganglion. J Thorac Cardiovasc Surg. 2003;126:1234–9.
29. Fujita K, Inoue G, Shimada Y, Yamada K, Takada K, et al. Portal vein embolisation for primary liver cancer complicating acute aortic dissection. Eur J Vasc Endovasc Surg. 2005;29:121–5.
30. Takeda M, Okamoto I, Nakagawa K. Survival outcome assessed according to tumor response and shrinkage pattern in patients with EGFR mutation-positive non-small cell lung cancer treated with gefitinib or erlotinib. J Thorac Oncol. 2014;9:200–4.
31. Faire-Finn C, Vicente D, Kurata T, Planchar D, Paz-Ares L, Vansteenkiste JF, et al. Four-year survival with durvalumab after chemoradiotherapy in stage III NSCLC—an update from the PACIFIC trial. J Thorac Oncol. 2021;16:680–7.
32. Riely GJ, Kris MG, Zhao B, Akhurst T, Milton DT, Moore E, et al. Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin Cancer Res. 2007;13:5150–5.
33. Hishida T, Yoshida J, Aokage K, Nagai K, Tsuboi M. Long-term outcome of surgical resection for residual or regrown advanced non-small cell lung carcinomas following EGFR-TKI treatment: report of four cases. Gen Thorac Cardiovasc Surg. 2016;64:429–33.
34. Wu YL, Tsuboi M, He J, John T, Grohe C, Majem M, et al. Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. N Engl J Med. 2020;383:1711–23.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.